Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER4 | P35408 | 18/20 | 0.69 |
| ▸ | NPC1 | O15118 | 1/20 | 0.53 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.53 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.53 |
| ▸ | POLB | P06746 | 1/20 | 0.53 |
| ▸ | MAPT | P10636 | 1/20 | 0.53 |
| ▸ | HPGD | P15428 | 1/20 | 0.53 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3535664 | 0.89 | PTGER4 (0.73) | PTGER4 | |
| SCHEMBL4119393 | 0.83 | PTGER4 (0.80) | PTGER4NPC1POLBHSD17B10TDP1 | |
| SCHEMBL1756460 | 0.82 | PTGER4 (1.00) | PTGER4 | |
| SCHEMBL6195330 | 0.82 | PTGER4 (0.68) | PTGER4NPC1KDM4EALDH1A1POLB | |
| SCHEMBL6191988 | 0.80 | PTGER4 (0.69) | PTGER4NPC1KDM4EALDH1A1POLB | |
| SCHEMBL3533472 | 0.78 | PTGER4 (0.77) | PTGER4KDM4EALDH1A1POLBMAPT | |
| SCHEMBL3531304 | 0.78 | PTGER4 (0.76) | PTGER4NPC1 | |
| SCHEMBL3537906 | 0.77 | PTGER4 (1.00) | PTGER4NPC1POLBHSD17B10TDP1 | |
| SCHEMBL3538597 | 0.76 | PTGER4 (0.78) | PTGER4KDM4EALDH1A1POLBMAPT | |
| SCHEMBL3534435 | 0.76 | PTGER4 (1.00) | PTGER4KDM4EALDH1A1POLBMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7858644-B2 | EP4 receptor antagonists | ASTERAND UK LIMITED (GB) | 2010-12-28 | — | — | US | disclosed |
| US-20090143437-A1 | EP4 RECEPTOR ANTAGONISTS | ASTERAND UK LIMITED (GB) | 2009-06-04 | — | — | US | disclosed |
| EP-1603893-A1 | EP4 RECEPTOR ANTAGONISTS | Pharmagene Laboratories Ltd (GB) | 2005-12-14 | — | — | EP | disclosed |
| WO-2004067524-A1 | EP4 RECEPTOR ANTAGONISTS | PHARMAGENE LABORATORIES LIMITED (GB) | 2004-08-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090143437-A1 | EP4 RECEPTOR ANTAGONISTS | PTGER4, NR4A1, NR4A2 | PTGER4 1/4885NPC1 3366/4885KDM4E 1843/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.